Kevin Ryan’s AlleyCorp raises new $335 million fund, all in on early-stage bets
Kevin Ryan knows how to change his mind. Consider psychedelics: Ryan—often called “the Godfather of NYC Tech”—was once skeptical that psychedelics could be viable treatments for depression or PTSD.
Reported by 1 outlet — Fortune. See all sources ↓
Kevin Ryan knows how to change his mind. Consider psychedelics: Ryan—often called “the Godfather of NYC Tech”—was once skeptical that psychedelics could be viable treatments for depression or PTSD. But in 2018, he read Michael Pollan’s How to Change Your Mind and encountered a wave of data. Now, he’s a key backer of the Yale Center for Psychedelic Research and cofounded Transcend Therapeutics, a psychoactive drug maker that sold in June for $1.2 billion.
Read the full report at Fortune ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Kevin Ryan knows how to change his mind. Consider psychedelics: Ryan—often called “the Godfather of NYC Tech”—was once skeptical that psychedelics could be viable treatments for depression or PTSD.
- How widely is it covered?
- 1 outlet, average source rating 6.0/10.
- When was it last updated?
- 12m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Kevin Ryan’s AlleyCorp raises new $335 million fund, all in on early-stage bets
Sources1TypeCoverageFortune